Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes
- 424 Downloads
The recent introduction of the second-generation long-acting analogue insulins degludec and insulin glargine U300 have increased the choice of basal insulin therapy for patients with type 2 diabetes. The pharmacokinetic and pharmacodynamic properties of these insulins result in a flatter profile that lasts over 24 h and provides an increased window of administration of 6 h once daily. Large-scale multicentre randomised clinical trial programmes (BEGIN for degludec U100 and U200 and EDITION for glargine U300) evaluating these insulin therapies against glargine U100 have demonstrated that they are either non-inferior or superior for glycaemic efficacy and safety, but less likely to result in severe or nocturnal hypoglycaemia than glargine U100. The disposable pen devices for these insulins have been designed with patient satisfaction and convenience in mind. No concerns have arisen with adverse events with insulin analogues or cardiovascular safety from the ORIGIN and DEVOTE trials. As they demonstrate equivalent glycaemic efficacy to other basal insulins, they should be considered more in selected patient groups including those with recurrent or increased risk of hypoglycaemia, especially severe or nocturnal episodes, in the elderly or those living alone, and in patients with multiple co-morbidities such as cardiovascular or renal disease.
The authors acknowledge support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care—East Midlands (NIHR CLAHRC—EM), the Leicester Clinical Trials Unit and the NIHR Leicester Biomedical Research Centre, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. No sources of funding were used to assist in the preparation of this article.
Compliance with Ethical Standards
Conflict of Interest
SC has received speaker fees or educational funding, or both, from Janssen, Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim and grants in support of investigator initiated trials from Boehringer Ingelheim and Janssen. KK has acted as a consultant and speaker for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Janssen, and Boehringer Ingelheim, has received grants in support of investigator and investigator-initiated trials from AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, Merck Sharp & Dohme, and Roche, and has served on advisory boards for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Janssen, and Boehringher Ingelheim. MJD reports personal fees from Novo Nordisk, Sanofi-Aventis, Eli Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceuticals International and grants from Novo Nordisk, Sanofi- Aventis, Eli Lilly, Boehringer Ingelheim, and Janssen.
- 4.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.CrossRefGoogle Scholar
- 6.Lipska KJ, Parker MM, Moffet HH, Huang ES, Karter AJ. Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA. 2018;320(1):53–62.CrossRefGoogle Scholar
- 9.International Diabetes F. IDF diabetes atlas. Brussels: Belgium; 2017.Google Scholar
- 14.Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–507.CrossRefGoogle Scholar
- 16.Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulinnaive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-totarget trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–42.CrossRefGoogle Scholar
- 28.Riddle MC, Bolli GB, Zieman M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–62.CrossRefGoogle Scholar
- 29.Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235–43.CrossRefGoogle Scholar
- 31.Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metabol. 2016;18(4):366–74.CrossRefGoogle Scholar
- 34.Lonn EM, Bosch J, Diaz R, et al. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care. 2013;36(9):2466–74.CrossRefGoogle Scholar
- 37.Kawaguchi Y, Sawa J, Sakuma N, Kumeda Y. Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: a randomized, open-label, cross-over study using continuous glucose monitoring profiles. J Diabetes Investig. 2018. https://doi.org/10.1111/jdi.12884.CrossRefPubMedGoogle Scholar
- 38.Sullivan SD, Bailey TS, Roussel R, et al. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab. 2018;20(9):2148–58.CrossRefGoogle Scholar
- 39.Meneghini L, Roussel R, Zhou FL, et al. Comparable Rates of Severe Hypoglycemia in People with Type 2 Diabetes (T2DM) at High Risk of Hypoglycemia Switching to either Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—The Lightning Real-World Predictive Modeling Study. American Diabetes Association. Orlando: ADA; 2018.Google Scholar
- 40.Sanofi. https://www.toujeo.com/how-to-use-toujeo-insulin. Accessed 25 Sept 2018.
- 42.NovoNordisk. https://www.tresibapro.com/dosing-and-device/tresiba-flextouch.html. Accessed 25 Sept 2018.
- 51.Yki-Jarvinen H, Bergenstal RM, Bolli GB, et al. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metabol. 2015;17(12):1142–9.CrossRefGoogle Scholar
- 54.Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units. mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units. mL−1. Diabetes Care. 2015;38(4):637–43.Google Scholar
- 56.Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–64.CrossRefGoogle Scholar
- 58.Sanofi. Toujeo SMPC. 03/2018. http://products.sanofi.us/toujeo/toujeo.pdf. Accessed 25 Sept 2018.
- 59.Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Jarvinen H. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patientlevel meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018;20(3):541–8.CrossRefGoogle Scholar
- 60.NovoNordisk. Tresiba SmPC. https://www.novo-pi.com/tresiba.pdf. Accessed 25 Sept 2018.
- 62.NHS Digital. National Diabetes Inpatient Audit (NaDIA), 2017.Google Scholar
- 65.Gough SC, Bode B, Woo V, et al. Efficacy and safety of a combination of insulin degludec and liraglutide (IDegLira) in patients with Type 2 diabetes after 1 year of treatment. Diabetic medicine. 2015;2(11):885–93.Google Scholar